

# Aman Seth

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5329828/publications.pdf>

Version: 2024-02-01

14  
papers

240  
citations

1478505

6  
h-index

1474206

9  
g-index

14  
all docs

14  
docs citations

14  
times ranked

652  
citing authors

#	ARTICLE	IF	CITATIONS
1	Topoisomerase Assays. Current Protocols in Pharmacology, 2012, 57, Unit 3.3..	4.0	82
2	ETV6-NTRK3 induces aggressive acute lymphoblastic leukemia highly sensitive to selective TRK inhibition. Blood, 2018, 132, 861-865.	1.4	53
3	Recipient Myeloid-Derived Immunomodulatory Cells Induce PD-1 Ligand-Dependent Donor CD4+Foxp3+ Regulatory T Cell Proliferation and Donor-Recipient Immune Tolerance after Murine Nonmyeloablative Bone Marrow Transplantation. Journal of Immunology, 2013, 191, 5764-5776.	0.8	31
4	Modeling and targeting of erythroleukemia by hematopoietic genome editing. Blood, 2021, 137, 1628-1640.	1.4	25
5	End-processing during non-homologous end-joining: a role for exonuclease 1. Nucleic Acids Research, 2011, 39, 970-978.	14.5	23
6	Aging affects response to cyclic tensile stretch: paradigm for intervertebral disc degeneration. , 2011, 22, 137-146.		15
7	Bidirectional immune tolerance in nonmyeloablative MHC-mismatched BMT for murine $\beta^2$ -thalassemia. Blood, 2017, 129, 3017-3030.	1.4	7
8	Recent Advances in Liposome Techniques and their Applications in Arthritis. Recent Patents on Biomedical Engineering, 2012, 5, 57-62.	0.5	1
9	An Evaluation of the Cytotoxic Effect of the Natural Product Aaptamine Against t(4;11) Leukemias. Blood, 2016, 128, 1624-1624.	1.4	1
10	Repair of Topoisomerase II-Mediated DNA Damage: Fixing DNA Damage Arising from a Protein Covalently Trapped on DNA. Cancer Drug Discovery and Development, 2012, , 381-407.	0.4	1
11	NUP98-KDM5A Fusion Induces Hematopoietic Cell Proliferation and Alters Myelo-Erythropoietic Differentiation. Blood, 2019, 134, 3775-3775.	1.4	1
12	Multiplex CRISPR/Cas9-Based Genome Editing of Mouse Hematopoietic Stem Cells Recapitulates Acute Erythroid Leukemia and Identifies Therapeutic Targets. Blood, 2018, 132, 5-5.	1.4	0
13	Loss of PTEN in Pediatric AML Confers Sensitivity to PARP Inhibition. Blood, 2021, 138, 3446-3446.	1.4	0
14	G3BP2-KIT drives leukemia amenable to kinase inhibition in Ph-like ALL. Blood Advances, 2022, , .	5.2	0